+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two approaches to support older adults and their family caregivers during the vulnerable transition from hospital to home. The study compares a patient-centered care transition program alone versus the same program enhanced with special strategies to engage and support family caregivers. This research aims to improve patient safety at home, reduce hospital and emergency visits, and lessen caregiver burden and stress. The study involves two groups one receiving a patient-centered program with assessments, discharge planning, education, and follow-up focused on the patient, and another group receiving these patient strategies plus family caregiver needs assessment, structured education, and skills building. The intervention is delivered through multiple hospitals across five states and uses telephone, video calls, and other technologies to reach participants and families. Participants will be older adults discharged home from hospital and their family caregivers. The study team will assess hospital-free days, patient readmissions, patient ability to do everyday activities, caregiver burden, caregiver self-efficacy, and satisfaction with care transitions. Data will be collected through interviews, questionnaires, and follow-up visits up to 180 days after discharge. The goal is to understand how family involvement affects health outcomes and caregiving experience during this transition period.

Age: 18Years +All GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are conducting a randomized, double-masked, multi-site clinical trial to evaluate the safety of Ex Vivo Corneal Cross Linking CXL of donor corneal tissue in people who have undergone high-risk penetrating keratoplasty. This study focuses on patients with corneal transplant failure characterized by significant corneal neovascularization. The trial aims to assess whether treating donor corneal tissue with CXL affects the safety of transplantation over a 24-month period. Participants are randomly assigned to receive either donor corneal tissue treated with 0.1% riboflavin Vitamin B2 and 20% dextran Photrexa Viscous & Photrexa with UV light exposure or untreated tissue without UV treatment. The treated tissue is prepared by a Corneal Tissue Bank according to current good tissue practices and then transplanted by participating institutions. The study compares outcomes between these two groups to determine any differences related to the cross-linking procedure. During the study, participants will be monitored for up to 24 months after their transplant to track adverse events and evaluate graft success. Assessments include safety measures, rates of graft failure, time to graft failure or rejection, and image-based evaluations of corneal tissue. This long-term follow-up helps researchers understand the impact of cross-linking on transplant outcomes and patient safety over time.

Age: 18Years +All GendersPhase 2
12 locations
R

Actively Recruiting

Researchers are collecting real-world data on the use of the commercially approved Intracept10 Intraosseous Nerve Ablation Systems to treat patients diagnosed with vertebrogenic pain, including those with chronic low-back pain and vertebrogenic pain syndrome. The study aims to better understand outcomes from this minimally invasive procedure in routine clinical settings. Participants will receive treatment with the Intracept10 Intraosseous Nerve Ablation device following local instructions for use. The study observes patients who undergo this nerve ablation therapy without assigning participants to different groups, as it is an observational study without randomization or placebo. Throughout the study, participants will be monitored over 60 months after the procedure. Researchers will assess changes in disability using the Oswestry Disability Index ODI and gather other outcome data to evaluate the impact of treatment. Participation involves regular follow-up to document treatment effects and safety over time.

Age: 18Years +All Genders
22 locations